Receptor tyrosine kinase Kit and gastrointestinal stromal tumours: An overview

Current Medicinal Chemistry

Volumn 18, Issue 19, 2011, Pages 2893-2903

  Sartini, S ^a   Dario, B ^a   Morelli, M ^a   Da Settimo, F ^a   La Motta, C ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

GISTs; Kit; Tyrosine kinase inhibitors

Indexed keywords

DASATINIB; EVEROLIMUS; IMATINIB; MASITINIB; MIDOSTAURIN; NILOTINIB; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; VATALANIB;

CARCINOGENESIS; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERANCE; EXON; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GENE INSERTION; HUMAN; LOW DRUG DOSE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TUMOR REGRESSION; WILD TYPE;

EID: 79959946624     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796150504     Document Type: Review

References (164)

1. Besmer, P.; Murphy, J. E.; George, P. C.; Qiu, F. H.; Bergold, P. J.; Lederman, L.; Snyder, Jr H. W.; Brodeur, D.; Zuckerman, E. E.; Hardy, W. D. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature, 1986, 320, 415-421. (Pubitemid 16097805)
2. Nocka, K.; Majumder, S.; Chabot, B.; Ray, P.; Cervone, M.; Bernstein, A.; Besmer, P. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice - evidence for an impaired c-kit kinase in mutant mice. Genes Dev., 1989, 3, 816-826.
3. Chabot, B.; Stephenson, D. A.; Chapman, V. M.; Besmer, P.; Bernstein, A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature, 1988, 335, 88-89.
4. Yarden, Y.; Kuang, W.-Y.; Yang-Feng, T.; Coussens, L.; Munemitsul, S.; Dull, T. J.; Chen, E.; Schlessinger, J.; Francke, U.; Ullrich, A. Human protooncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J., 1987, 6, 3341-3351.
5. Besmer, P. The kit ligand encoded at the murine Steel locus: a pleiotropic growth and differentiation factor. Curr. Opin. Cell. Biol., 1991, 3, 939-946. (Pubitemid 121001228)
6. Smith, M. A.; Pallister, C. J.; Smith, J. G. Stem cell factor: biology and relevance to clinical practice. Acta Haematologica, 2001, 105, 143-150. (Pubitemid 32679596)
7. Lennartsson, J.; Jelacic, T.; Linnekin, D.; Shivakrupa, R. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells, 2005, 23, 16-43. (Pubitemid 40105289)
8. Coussens, L.; Van Beveren, C.; Smith, D.; Chen, E.; Mitchell, R. L.; Isacke, C. M.; Verma, I. M.; Ullrich, A. Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus. Nature, 1986, 320, 277-280. (Pubitemid 16040245)
9. Fantl, W. J.; Johnson, D. E.; Williams, L. T. Signalling by receptor tyrosine kinases. Annu. Rev. Biochem., 1993, 62, 453-481. (Pubitemid 23237878)
10. Ashman, L. K. The biology of stem cell factor and its receptor c-Kit. Int. J. Biochem. Cell Biol., 1999, 31, 1037-1051. (Pubitemid 29454545)
11. Rosnet, O.; Birnbaum, D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit. Rev. Oncol., 1993, 4, 595-613. (Pubitemid 2002495)
12. Claesson-Welsh, L.; Eriksson, A.; Westermark, B.; Heldin, C. H. cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor. Proc. Natl. Acad. Sci. USA, 1989, 86, 4917-4921. (Pubitemid 19182209)
13. Edling, C. E.; Hallberg, B. c-Kit - a hematopoietic cell essential receptor tyrosine kinase. Int. J. Biochem. Cell Biol., 2007, 39, 1995-1998. (Pubitemid 47376824)
14. Crosier, P. S.; Ricciardi, S. T.; Hall, L. R.; Vitas, M. R.; Clark, S. C.; Crosier, K. E. Expression of isoforms of the human receptor tyrosine kinase c-Kit in leukemic cell lines and acute myeloid leucemia. Blood, 1993, 82, 1151-1158. (Pubitemid 23253988)
15. Yuzawa, S.; Opatowsky, Y.; Zhang, Z.; Mandiyan, V.; Lax, I.; Schlessinger, J. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell, 2007, 130, 323-334. (Pubitemid 47081138)
16. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell, 1990, 61, 203-212.
17. Zhang, Z.; Zhang, R.; Joachimiak, A.; Schlessinger, J.; Kong, X.-P. Crystal structure of human stem cell factor: implication for stem cell factor receptor dimerization and activation. Proc. Natl. Acad. Sci. USA, 2000, 97, 7732-7737. (Pubitemid 30460716)
18. Otto, K. G.; Jin, L.; Spencer, D. M.; Blau, C. A. Cell proliferation through forced engagement of c-Kit and Flt-3. Blood, 2001, 97, 3662-3664.
19. Hirota, S.; Ohashi, A.; Nishida, T.; Isozaki, K.; Kinoshita, K.; Shinomura, Y.; Kitamura, Y. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology, 2003, 125, 660-667. (Pubitemid 37070684)
20. Mol, C. D.; Lim, K. B.; Sridhar, V.; Zou, H.; Chien, E. Y. T.; Sang, B.-C.; Nowakowski, J.; Kassel, D. B.; Cronin, C. N.; McRee, D. E. Structure of a c-Kit product complex reveals the basis for kinase transactivation. J. Biol. Chem., 2003, 278, 31461-31464. (Pubitemid 37048320)
21. Mol, C. D.; Dougan, D. R.; Schneider, T. R.; Skene, R. J.; Kraus, M. L.; Scheibe, D. N.; Snell, G. P.; Zou, H.; Sang, B. C.; Wilson, K. P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem., 2004, 279, 31655-31663. (Pubitemid 39037836)
22. Linnekin, D.; DeBerry, C. S.; Mou, S. Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. J. Biol. Chem., 1997, 272, 27450-27455. (Pubitemid 27452714)
23. Timokhina, I.; Kissel, H.; Stella, G.; Besmer, P. Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation. EMBO J., 1998, 17, 6250-6262. (Pubitemid 28497798)
24. Lennartsson, J.; Blume-Jensen, P.; Hermanson, M.; Pontén, E.; Carlberg, M.; Rönnstrand, L. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene, 1999, 18, 5546-5553. (Pubitemid 29481501)
25. Shivakrupa, R.; Linnekin, D. Lyn contributes to regulation of multiple Kitdependent signaling pathways in murine bone marrow mast cells. Cell. Signal., 2005, 17, 103-109. (Pubitemid 39286785)
26. Wollberg, P.; Lennartsson, E.; Gottfridsson, E.; Yoshimura, A.; Rönnstrand, L. The adapter protein APS associates with the multifunctional docking sites Tyr568 and Tyr 936 in c-Kit. Biochem. J., 2003, 370, 1033-1038. (Pubitemid 36399098)
27. Price, D. J.; Rivnay, B.; Fu, Y.; Jiang, S.; Avraham, S.; Avraham, H. Direct association of Csk homologous kinase (CHK) with the diphosphorylated site Tyr568/570 of the activated c-KIT in megakaryocytes. J. Biol. Chem., 1997, 272, 5915-5920. (Pubitemid 27102427)
28. Kozlowski, M.; Larose, L.; Lee, F.; Le, D. M.; Rottapel, R.; Siminovitch, A. SHP-1 Binds and negatively modulates the c-Kit receptor by interaction with Tyrosine 569 in the c-Kit juxtamembrane Domain. Mol. Cell. Biol., 1998, 18, 2089-2099. (Pubitemid 28152658)
29. Thömmes, K.; Lennartsson, J.; Carlberg, M.; Rönnstrand, L. Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor. Biochem. J., 1999, 341, 211-216. (Pubitemid 29359067)
30. Lev, S.; Givol, D.; Yarden, Y. Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase. Proc. Natl. Acad. Sci. USA, 1992, 89, 678-682.
31. Serve, H.; Hsu, Y. C.; Besmer, P. Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. J. Biol. Chem., 1994, 269, 6026-6030. (Pubitemid 24242986)
32. Gommerman, J. L.; Sittaro, D.; Klebasz, N. Z.; Williams, D. A.; Berger, S. A. Differential stimulation of c-Kit mutants by membrane-bound and soluble steel factor correlates with leukemic potential. Blood, 2000, 96, 3734-3742.
33. Lennartsson, J.; Wernstedt, C.; Engström, U.; Hellman, U.; Rönnstrand, L. Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent phosphorylation site mediating interaction with c-Crk. Exp. Cell Res., 2003, 288, 110-118. (Pubitemid 36871001)
34. Yoon, S.; Seger, R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors, 2006, 24, 21-44. (Pubitemid 43108774)
35. Vosseller, K.; Stella, G.; Yee, N. S.; Besmer, P. c-kit receptor signaling through its phosphatidylinositide-3′-kinase-binding site and protein kinase C: role in mast cell enhancement of degranulation, adhesion, and membrane ruffling. Mol. Cell Biol., 1997, 8, 909-922. (Pubitemid 27255030)
36. Wandzioch, E.; Edling, C. E.; Palmer, R. H.; Carlsson, L.; Hallberg, B. Activation of the MAP kinase pathway by c-Kit is PI-3 kinase dependent in hematopoietic progenitor/stem cell lines. Blood, 2004, 104, 51-57. (Pubitemid 38879837)
37. Paling, N. R.; Wheadon, H.; Bone, H. K.; Welham, M. J. Regulation of embryonic stem cell self-renewal by phosphoinositide 3-kinase-dependent signaling. J. Biol. Chem., 2004, 279, 48063-48070. (Pubitemid 39540959)
38. Young, S. M.; Cambareri, A. C.; Ashman, L. K. Role of c-KIT expression level and phosphatidylinositol 3-kinase activation in survival and proliferative responses of early myeloid cells. Cell. Signal., 2006, 18, 608-620. (Pubitemid 43113292)
39. Sun, J.; Pedersen, M.; Rönnstrand, L. The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction. J. Biol. Chem., 2009, 284, 11039-11047.
40. Haneline, L. S.; White, H.; Yang, F. C.; Chen, S.; Orschell, C.; Kapur, R.; Ingram, D. A. Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo. Blood, 2006, 107, 1375-1382. (Pubitemid 43242371)
41. Blume-Jensen, P.; Rönnstrand, L.; Gout, I.; Waterfield, M. D.; Heldin, C. H. Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C. J. Biol. Chem., 1994, 269, 21793-21802. (Pubitemid 24274822)
42. Minden, A.; Lin, A.; Claret, F. X.; Abo, A.; Karin, M. Selective activation of the JNK signaling cascade and c-Jun. transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell, 1995, 81, 1147-1157.
43. Engström, M.; Karlsson, R.; Jönsson, J. I. Inactivation of the forkhead transcription factor FoxO3 is essential for PKB-mediated survival of hematopoietic progenitor cells by kit ligand. Exp. Ematol., 2003, 31, 316-323.
44. Cancelas, J. A.; Jansen, M.; Williams, D. A. The role of chemokine activation of Rac GTPases in hematopoietic stem cell marrow homing, retention, and peripheral mobilization. Exp. Hematol., 2006, 34, 976-985. (Pubitemid 44080381)
45. Blume-Jensen, P.; Janknecht, R.; Hunter, T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol., 1998, 8, 779-782. (Pubitemid 28301165)
46. Han, J.; Luby-Phelps, K.; Das, B.; Shu, X.; Xia, Y.; Mosteller, R. D.; Krishna, U. M.; Falck, J. R.; White, M. A.; Broek, D. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science, 1998, 279, 558-560. (Pubitemid 28067283)
47. Han, J.; Das, B.; Wei, W.; Van Aelst, L.; Mosteller, R. D.; Khosravi-Far, R.; Westwick, J. K.; Der, C. J.; Broek, D. Lck regulates Vav activation of members of the Rho family of GTPases. Mol. Cell Biol., 1997, 17, 1346-1353. (Pubitemid 27097363)
48. Nimnual, A. S.; Yatsula, B. A.; Bar-Sagi, D. Coupling of Ras and Rac guanosine triphosphatases through the Ras exchanger Sos. Science, 1998, 279, 560-563. (Pubitemid 28067284)
49. Zeng, S.; Xu, Z.; Lipkowitz, S.; Longley, J. B. Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl). Blood, 2005, 105, 226-232. (Pubitemid 40053087)
50. Roskoski, R. Jr. Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem. Biophys. Res. Commun., 2005, 338, 1307-1315. (Pubitemid 41608395)
51. Edling, C. E.; Pedersen, M.; Carlsson, L.; Rönnstrand, L.; Palmer, R. H.; Hallberg, B. Haematopoietic progenitor cells utilise conventional PKC to suppress PKB/Akt activity in response to c-Kit stimulation. Br. J. Hematol., 2007, 136, 260-268. (Pubitemid 46020753)
52. Kitamura, Y.; Hirota, S. Kit as a human oncogenic tyrosine kinase. Cell. Mol. Life Sci., 2004, 61, 2924-2931. (Pubitemid 40104590)
53. Longley, B. J.; Reguera, M. J.; Ma, Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk. Res., 2001, 25, 571-576. (Pubitemid 32506764)
54. Furitsu, T.; Tsujimura, T.; Tono, T.; Ikeda, H.; Kitayama, H.; Koshimizu, U.; Sugahara, H.; Butterfield, J. H.; Ashman, L. K.; Kanayama, Y.; Matsuzawa, Y.; Kitamura, Y.; Kanakura Y. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest., 1993, 92, 1736-1744. (Pubitemid 23304537)
55. Carlomagno, F.; Santoro, M. Receptor tyrosine kinases as targets for anticancer therapeutics. Curr. Med. Chem., 2005, 12, 1773-1781. (Pubitemid 40894999)
56. Longley, B. J. Jr; Metcalfe, D. D.; Tharp, M.; Wang, X.; Tyrrell, L. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. USA, 1999, 96, 1609-1614. (Pubitemid 29098499)
57. Nagata, H.; Worobec, A. S.; Oh, C. K.; Chowdhury, B. A.; Tannenbaum, S.; Suzuki, Y. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA, 1995, 92, 10560-10564.
58. Hartmann, K.; Henz, B. M. Mastocytosis: recent advances in defining the disease. B r. J. Dermatol., 2001, 144, 682-695. (Pubitemid 32374769)
59. Wolfgang, R. S.; Horny, H. S.; Valent, P. Spectrum of associated clonal hematologic non-mast cell lineage disorder occurring in patients with systemic mastocytosis. Int. Arch. Allergy Immunol., 2002, 127, 140-142. (Pubitemid 34264203)
60. Gari, M.; Goodeve, A.; Wilson, G.; Winship, P.; Langabeer, S.; Linch, D.; Vandenberghe, E.; Peake, I.; Reilly, J. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br. J. Haematol., 1999, 105, 894-900. (Pubitemid 29309094)
61. Jaffe, E. S.; Krenacs, L.; Kumar, S.; Kingma, D. W.; Raffeld, M. Extranodal peripheral T-cell and NK-cell neoplasm. Am. J. Clin. Pathol., 1999, 111, S46-S55. (Pubitemid 29024949)
62. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature, 2001, 411, 355-356.
63. Miettinen, M.; Lasota, J. KIT (CD 117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl. Immunohistochem. Mol. Morphol., 2005, 13, 205-220. (Pubitemid 41209013)
64. Tian, Q.; Frierson, H. F. Jr; Krystal, G. W.; Moskaluk, C. A. Activating c-kit gene mutations in human germ cell tumors. Am. J. Phatol., 1999, 154, 1643-1647. (Pubitemid 29262845)
65. Curtin, J. A.; Busam, K.; Pinkel, D.; Bastian, B. C. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol., 2006, 24, 4340-4346. (Pubitemid 46630793)
66. Casali, P. G.; Blay, J. B. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2010, 21, v98-v102.
67. Morgan, B. K.; Compton, C.; Talbert, M.; Gallagher, W. J.; Wood, W. C. Benign smooth muscle tumors of the gastrointestinal tract: a 24-year experience. Ann. Surg., 1990, 211, 63-66. (Pubitemid 20027885)
68. Taniguchi, M.; Nishida, T.; Hirota, S.; Isozaki, K.; Ito, T.; Nomura, T.; Matsuda, H.; Kitamura, Y. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res., 1999, 59, 4297-4300. (Pubitemid 29418746)
69. Tarn, C.; Merkel, E.; Canutescu, A. A.; Shen, W.; Skorobogatko, Y.; Heslin, M. J.; Eisenberg, B.; Birbe, R.; Patchefsky, A.; Dunbrack, R.; Arnoletti, J. P.; von Mehren, M.; Godwin, A. K. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin. Cancer Res., 2005, 11, 3668-3677. (Pubitemid 40685583)
70. Lasota, J.; Miettinen, M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology, 2008, 53, 245-266.
71. Hirota, S.; Isozaki, K.; Moriyama, Y.; Hashimoto, K.; Nishida, T.; Ishiguro, S.; Kawano, K.; Hanada, M.; Kurata, A.; Takeda, M.; Muhammad Tunio, G.; Matsuzawa, Y.; Kanakura, Y.; Shinomura, Y.; Kitamura, Y. Gain-offunction mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279, 577-580. (Pubitemid 28067289)
72. Hartmann, K.; Wardelmann, E.; Ma, Y.; Merkelbach-Bruse, S.; Preussner, L. M.; Woolery, C.; Baldus, S. E.; Heinicke, T.; Thiele, J.; Buettner, R.; Longley, B. J. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology, 2005, 129, 1042-1046. (Pubitemid 41242694)
73. Lux, M. L.; Rubin, B. P.; Biase, T. L.; Chen, C. J.; Maclure, T.; Demetri, G.; Xiao, S.; Singer, S.; Fletcher, C. D.; Fletcher, J. A. Kit extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol., 2000, 156, 791-795. (Pubitemid 30626936)
74. Lasota, J.; Wozniak, A.; Sarlomo-Rikala, M.; Rys, J.; Kordek, R.; Nassar, A.; Sobin, L. H.; Miettinen, M. Mutation in exons 9 and 13 of Kit gene are rare events in gastrointestinal stromal tumors. Am. J. Pathol., 2000, 157, 1091-1095.
75. Fletcher, J. A.; Rubin, B. P. KIT mutations in GIST. Curr. Opin. Genet. Develop., 2007, 17, 3-7. (Pubitemid 46109300)
76. Romagnoli, S.; Graziani, D.; Bramerio, M.; Gambacorta, M.; Colombo, P.; Roncalli, M.; Coggi, G.; Bosari, S. Immunostochemical profile and c-kit mutations in gastrointestinal stromal tumors. Pathology, Res. Pract., 2005, 201, 71-81. (Pubitemid 40443820)
77. Hirota, S.; Nishida, T.; Isozaki, K.; Taniguchi, M.; Nakamura, J.; Okazaki, T.; Kitamura, Y. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J. Pathol., 2001, 193, 505-510. (Pubitemid 32266820)
78. Rubin, B. P.; Singer, S.; Tsao, C.; Duensing, A.; Lux, M. L.; Ruiz, R.; Hibbard, M. K.; Chen, C. J.; Xiao, S.; Tuveson, D. A.; Demetri, G. D.; Fletcher, C. D.; Fletcher, J. A. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res., 2001, 61, 8118-8121. (Pubitemid 33091601)
79. Duensing, A.; Medeiros, F.; McConarty, B.; Joseph, N. E.; Panigrahy, D.; Singer, S.; Fletcher, C. D.; Demetri, G. D.; Fletcher, J. A. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene, 2004, 23, 3999-4006. (Pubitemid 38747928)
80. Zhu, M.-J.; Ou, W.-B.; Fletcher, C. D. M.; Cohen, P. S.; Demetri, G. D.; Fletcher, J. A. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance. Oncogene, 2007, 26, 6386-6395. (Pubitemid 47494217)
81. Heinrich, M. C.; Corless, C. L.; Duensing, A.; McGreevey, L.; Chen, C.-J.; Joseph, N.; Singer, S.; Griffith, D. J.; Haley, A.; Town, A.; Dimetri, G. D.; Fletcher, C. D. M.; Fletcher, J. A. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors. Science, 2003, 299, 708-710. (Pubitemid 36159485)
82. Martin-Broto, J.; Rubio, L.; Alemany, R.; Lopez-Guerrero, J. A. Clinical implications of KIT and PDGFRA genotyping in GIST. Clin. Trans. Oncol., 2010, 12, 670-676.
83. Reichardt, P.; Hogendoorn, P. C.; Tamborini, E.; Loda, M.; Gronchi, A.; Poveda, A.; Schöffski, P. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. Semin. Oncol., 2009, 36, 290-301.
84. Coindre, J. M.; Emile, J. F.; Monges, G.; Ranchère-Vince, D.; Scoazec, J. Y. Gastrointestinal stromal tumors: definition, histological, immunohistochemical, and molecular features, and diagnostic strategy. Ann. Pathol., 2005, 25, 358-385. (Pubitemid 43245507)
85. Tarn, C.; Rink, L.; Merkel, E.; Flieder, D.; Pathak, H.; Koumbi, D.; Testa, J. R.; Eisenberg, B.; von Mehren, M.; Godwin, A. K. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc. Natl. Acad. Sci. USA, 2008, 105, 8387-8392. (Pubitemid 351904765)
86. Pantaleo, M. A.; Astolfi, A.; Di Battista, M.; Heinrich, M. C.; Paterini, P.; Scotlandi, K.; Santini, D.; Catena, F.; Manara, M. C.; Nannini, M.; Maleddu, A.; Saponara, M.; Lolli, C.; Formica, S.; Biasco, G. Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int. J. Cancer, 2009, 125, 2991-2994.
87. Janeway, K. A.; Zhu, M. J.; Barretina, J.; Perez-Atayde, A.; Demetri, G. D.; Fletcher, J. A. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int. J. Cancer, 2010, 127, 2718-2722.
88. Agaimy, A.; Terracciano, L. M.; Dirnhofer, S.; Tornillo, L.; Foerster, A.; Hartmann, A.; Bihl, M. P. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J. Clin. Pathol., 2009, 62, 613-616.
89. Hostein, I.; Faur, N.; Primois, C.; Boury, F.; Denard, J.; Emile, J. F.; Bringuier, P. P.; Scoazec, J. Y.; Coindre, J. M. BRAF mutation status in gastrointestinal stromal tumors. Am. J. Clin. Pathol., 2010, 133, 141-148.
90. Zimmermann, J.; Buchdunger, E.; Mett, H.; Meyer, T.; Lydon, N. B. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett., 1997, 7, 187-192. (Pubitemid 27046418)
91. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Müller, M.; Druker, B. J.; Lydon, N. B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 1996, 56, 100-104.
92. Buchdunger, E.; Cioffi, C. L.; Law, N.; Stover, D.; Ohno-Jones, S.; Druker, B. J.; Lydon, N. B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction by c-Kit and platelet-derived mediated growth factor receptors. JPET, 2000, 295, 139-145.
93. Heinrich, M. C.; Griffith, D. J.; Druker, B. J.; Wait, C. L.; Ott, K. A.; Zigler, A. J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood, 2000, 96, 925-32. (Pubitemid 30618049)
94. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 1996, 2, 561-566.
95. Dewar, A. L.; Cambareri, A. C.; Zannettino, A. C.; Miller, B. L.; Doher, K. V.; Hughes, T. P.; Lyons, A. B. Macrophage colony stimulating factor receptor cfms is a novel target of imatinib. Blood, 2005, 105, 3127-3132.
96. Druker, B. J.; Sawyers, C. L.; Kantarjian, H.; Resta D. J.; Reese, S. F.; Ford, J. M.; Capdeville, R.; Talpaz, M. Activity of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 2001, 344, 1038-1042. (Pubitemid 32267973)
97. Joensuu, H.; Roberts, P. J.; Sarlomo-Rikala, M.; Andersson, L. C.; Tervahartiala, P.; Tuveson, D.; Silberman, S.; Capdeville, R.; Dimitrijevic, S.; Druker, B.; Demetri, G. D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med., 2001, 344, 1052-1056. (Pubitemid 32267975)
98. van Oosterom, A. T.; Judson, I.; Verweij, J.; Stroobants, S.; di Paola, D. E.; Dimitrijevic, S.; Martens, M.; Webb, A.; Sciot, R.; Van Glabbeke, M.; Silberman, S.; Nielsen, O. S.; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet, 2001, 358, 1421-1423.
99. van Oosterom, A. T.; Judson, I.; Verweij, J.; Stroobants, S.; Dumez, H.; Paola, D. E.; Sciot, R.; Van Glabbeke, M.; Dimitrijevic, S.; Nielsen, O. S.; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Update of phase I study of imatinib (ST1571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer, 2002, 38, S83-S87.
100. ®, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer, 2003, 39, 2006-2011. (Pubitemid 37297756)
101. Demetri, G. D.; von Mehren, M.; Blanke, C. D.; Van den Abbeele, A. D.; Eisenberg, B.; Roberts, P. J.; Heinrich, M. C.; Tuveson, D. A.; Singer, S.; Janicek, M.; Fletcher, J. A.; Silverman, S. G.; Silberman, S. L.; Capdeville, R.; Kiese, B.; Peng, B.; Dimitrijevic, S.; Druker, B. J.; Corless, C.; Fletcher, C.; Joensuu, H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Eng. J. Med., 2002, 347, 472-480. (Pubitemid 34879334)
102. Blanke, C. D.; Demetri, G. D.; von Mehren, M.; Heinrich, M. C.; Eisenberg, B.; Fletcher, J. A.; Corless, C. L.; Fletcher, C. D.; Roberts, P. J.; Heinz, D.; Wehre, E.; Nikolova, Z.; Joensuu, H. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol., 2008, 26, 620-625. (Pubitemid 351264357)
103. Blanke, C. D.; Rankin, C.; Demetri, G. D.; Ryan, C. W.; von Mehren, M.; Benjamin, R. S.; Raymond, A. K.; Bramwell, V. H.; Baker, L. H.; Maki, R. G.; Tanaka, M.; Hecht, J. R.; Heinrich, M. C.; Fletcher, C. D.; Crowley, J. J.; Borden, E. C. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol., 2008, 26, 626-632. (Pubitemid 351264358)
104. Verweij, J.; Casali, P. G.; Zalcberg, J.; LeCesne, A.; Reichardt, P.; Blay, J. Y.; Issel, R.; van Oosterom, A.; Hogendoorn, P. C.; Van Glabbeke, M.; Bertulli, R.; Judson, I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet, 2004, 364, 1127-1134. (Pubitemid 39296599)
105. Gleevec prescribing information. available from: http://www.pharma.us. novartis.com/product/pi/pdf/gleevec-tabs.pdf. (Accessed February 15, 2011)
106. Dematteo, R. P.; Ballman, K. V.; Antonescu, C. R.; Maki, R. G.; Pisters, P. W.; Demetri, G. D.; Blackstein, M. E.; Blanke, C. D.; von Mehren, M.; Brennan, M. F.; Patel, S.; McCarter, M. D.; Polikoff, J. A.; Tan, B. R.; Owzar, K. American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, doubleblind, placebo-controlled trial. Lancet, 2009, 373, 1097-1104.
107. Cohen, M. H.; Cortazar, P.; Justice, R.; Pazdur, R. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. Oncologist, 2010, 15, 300-307.
108. Essat, M.; Cooper, K. Imatinib as adjuvant therapy for gastrointestinal stromal tumours - a systematic review. J. Clin. Cancer, 2011, 128, 2202-2214.
109. Reichart, P. Optimising therapy for GIST patients. EJC Supplements, 2006, 4, 19-26.
110. Heinrich, M. C.; Corless, C. L.; Demetri, G. D.; Blanke, C. D.; von Mehren, M.; Joensuu, H.; McGreevey, L. S.; Chen, C. J.; Van den Abbeele, A. D.; Druker, B. J.; Kiese, B.; Eisenberg, B.; Roberts, P. J.; Singer, S.; Fletcher, C. D.; Silberman, S.; Dimitrijevic, S.; Fletcher, J. A. Kinase mutations and imatinib mesylate response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol., 2003, 21, 4342-4349. (Pubitemid 46621810)
111. Debiec-Rychter, M.; Sciot, R.; Le Cesne, A.; Schlemmer, M.; Hohenberger, P.; van Oosterom, A. T.; Blay, J. Y.; Leyvraz, S.; Stul, M.; Casali, P. G.; Zalcberg, J.; Verweij, J.; Van Glabbeke, M.; Hagemeijer, A.; Judson, I.; EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group. Kit mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer, 2006, 42, 1093-1103.
112. Gounder, M. M.; Maki, R. G. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother. Pharmacol., 2011, 67, S25-S43.
113. Heinrich, M. C.; Corless, C. L.; Blanke, C. D.; Demetri, G. D.; Joensuu, H.; Roberts, P. J.; Eisenberg, B. L.; von M. M.; Fletcher, C. D.; Sandau, K.; McDougall, K.; Ou, W. B.; Chen, C. J.; Fletcher J. A. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol., 2006, 24, 4764-4774. (Pubitemid 46630941)
114. Wardelmann, E.; Thomas, N.; Merkelbach-Bruse, S.; Pauls, K.; Speidel, N.; Buttner, R.; Bihl, H.; Leutner, C. C.; Heinicke, T.; Hohenberger, P. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol., 2005, 6, 249-251. (Pubitemid 40450717)
115. Antonescu, C. R.; Besmer, P.; Guo, T.; Arkun, K.; Hom, G.; Koryotowski, B.; Leversha, M. A.; Jeffrey, P. D.; Desantis, D.; Singer, S.; Brennan, M. F.; Maki, R. G.; DeMatteo, R. P. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer Res., 2005, 11, 4182-4190. (Pubitemid 40791584)
116. Chen, L. L.; Trent, J. C.; Wu, E. F.; Fullen, G. N.; Ramdas, L.; Zhang, W.; Raymond, A. K.; Prieto, V. G.; Oyedeji, C. O.; Hunt, K. K.; Pollock, R. E.; Feig, B. W.; Hayes, K. J.; Choi, H.; Macapinlac, H. A.; Hittelman, W.; Velasco, M. A.; Patel, S.; Burgess, M. A.; Benjamin, R. S.; Frazier, M. L. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res., 2004, 64, 5913-5919. (Pubitemid 39129383)
117. Tamborini, E.; Bonadiman, L.; Greco, A.; Albertini, V.; Negri, T.; Gronchi, A.; Bertulli, R.; Colecchia, M.; Casali, P. G.; Pierotti, M. A.; Pilotti, S. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology, 2004, 127, 294-299. (Pubitemid 38962296)
118. Heinrich, M. C.; Corless, C. L.; Blanke, C. D.; Demetri, G. D.; Joensuu, H.; Roberts, P. J.; Eisenberg, B. L.; von Mehren, M.; Fletcher, C. D.; Sandau, K.; McDougall, K.; Ou, W. B.; Chen, C. J.; Fletcher, J. A. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol., 2006, 96, 925-932.
119. Roberts, K. G.; Odell, A. F.; Byrnes, E. M.; Baleato, R. M.; Griffith, R.; Lyons, A. B.; Ashman, L. K. Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol. Cancer Res., 2007, 6, 1159-1166. (Pubitemid 46554587)
120. Gajiwala, K. S.; Wu, J. C.; Christensen, J.; Deshmukh, G. D.; Diehl, W.; DiNitto J. P.; English, J. M.; Greig, M. J.; He, Y.-A.; Jacques, S. L.; Lunney, E. A.; McTigue, M.; Molina, D.; Quenzer, T.; Wells, P. A.; Yu, X.; Zhang, Y.; Zou, A.; Emmett, M. R.; Marshall, A. G.; Zhang, H.-M.; Demetri, G. D. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc. Natl. Acad. Sci. USA, 2009, 106, 1542-1547.
121. Corless, C. L.; Heinrich, M. C. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu. Rev. Pathol. Mech. Dis., 2008, 3, 557-586. (Pubitemid 351488293)
122. Tuma, R. S. Disease progression in some cancers may be due to low blood levels of targeted therapies. J. Natl. Cancer Inst., 2008, 100, 912-913.
123. Demetri, G. D.; Wang, Y.; Wehrle, E.; Racine, A.; Nikolova, Z.; Blanke, C. D.; Joensuu, H.; von Mehren, M. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J. Clin. Oncol., 2009, 27, 3141-3147.
124. von Mehren, M.; Widmer, N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat. Rev., 2011, 37, 291-299.
125. Yoo, C.; Ryu, M.-H.; Ryoo, B.-Y.; Beck, M. Y.; Chang, H.-M.; Lee, J.-L.; Kim, T. W.; Kang, Y.-K. Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. Invest. New
126. Sarcoma Alliance for Research through Collaboration. Study of dose escalation versus no dose escalation of imatinib in metastatic gastrointestinal stromal tumors (GIST) patients. ClinicalTrials.gov identifier NCT01031628. US National Institute of Health, ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ (Accessed February 15, 2011).
127. Sablin, M. P.; Dreyer, C.; Colichi, C.; Bouattour, M.; Delbaldo, C.; Faivre, S.; Raymond, E. Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development. Exp. Opin. Drug Metab. Toxicol., 2010, 6, 1005-1015.
128. Goodman, V. L.; Rock, E. P.; Dagher, R.; Ramchandani, R. P.; Abraham, S.; Gobburu, J. V.; Booth, B. P.; Verbois, S. L.; Morse, D. E.; Liang, C. Y.; Chidambaram, N.; Jiang, J. X.; Tang, S.; Mahjoob, K.; Justice, R.; Pazdur R. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. J. Clin. Oncol., 2007, 13, 1367-1373. (Pubitemid 46450424)
129. Joensuu, H.; Trent, J. C.; Reichardt, P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat. Rev., 2011, 37, 75-88.
130. Mena, A. C.; Pulido, E. G.; Guillén-Ponce, C. Understanding the molecularbased mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs, 2010, 21, S3-S11.
131. Demetri, G. D.; van Oosterom, A. T.; Garrett, C. R.; Blackstein, M. E.; Shah, M. H.; Verweij, J.; McArthur, G.; Judson, I. R.; Heinrich, M. C.; Morgan, J. A.; Desai, J.; Fletcher, C. D.; George, S.; Bello, C. L.; Huang, X.; Baum, C. M.; Casali, P. G. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 2006, 368, 1329-1338. (Pubitemid 44528723)
132. Younus, J.; Verma, S.; Franek, J.; Coakley, N. Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence. Curr. Oncol., 2010, 17, 4-10.
133. Fabbro, D.; Ruetz, S.; Bodis, S.; Pruschy, M.; Csermak, K.; Man, A.; Campochiaro, P.; Wood, J.; O'Reilly, T.; Meyer, T. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anti-Cancer Drug Des., 2000, 15, 17-28. (Pubitemid 30364896)
134. Growney, J. D.; Clark, J. J.; Adelsperger, J.; Stone, R.; Fabbro, D.; Griffin, J. D.; Gilliland, D. G. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood, 2005, 106, 721-724. (Pubitemid 40981272)
135. Gotlib, J.; Berubé, C.; Growney, J. D.; Chen, C. C.; George, T. I.; Williams, C.; Kajiguchi, T.; Ruan, J.; Lilleberg, S. L.; Durocher, J. A.; Lichy, J. H.; Wang, Y.; Cohen, P. S.; Arber, D. A.; Heinrich, M. C.; Neckers, L.; Galli, S. J.; Gilliland, D. G.; Coutré, S. E. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood, 2005, 106, 2865-2870. (Pubitemid 41510766)
136. Gleixner, K. V.; Mayerhofer, M.; Aichberger, K. J.; Derdak, S.; Sonneck, K.; Böhm, A.; Gruze, A.; Samorapoompichit, P.; Manley, P. W.; Fabbro, D.; Pickl, W. F.; Sillaber, C.; Valent, P. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood, 2006, 107, 752-759. (Pubitemid 43076402)
137. Coppin, C. Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics, 2010, 4, 91-101.
138. Schöffski, P.; Reichardt, P.; Blay, J. Y.; Dumez, H.; Morgan, J. A.; Ray-Coquard, I.; Hollaender, N.; Jappe, A.; Demetri, G. D. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann. Oncol., 2010, 21, 1990-1998.
139. Maurel, J.; Martins, A. S.; Poveda, A.; López-Guerrero, J. A.; Cubedo, R.; Casado, A.; Martínez-Trufero, J.; Ramón Ayuso, J.; Lopez-Pousa, A.; Garcia-Albeniz, X.; Garcia del Muro, X.; de Alava, E. Imatinib plus lowdose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. Cancer, 2010, 116, 3692-3701.
140. Reynoso, D.; Nolden, L. K.; Yang, D.; Dumont, S. N.; Conley, A. P.; Dumont, A. G.; Zhou, K.; Duensing, A.; Trent, J. C. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. Mol. Oncol., 2011, 5, 93-104.
141. Schittenhelm, M. M.; Shiraga, S.; Schroeder, A.; Corbin, A. S.; Griffith, D.; Lee, F. Y.; Bokemeyer, C.; Deininger, M. W.; Druker, B. J.; Heinrich, M. C. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res., 2006, 66, 473-481. (Pubitemid 43166056)
142. Dewaele, B.; Wasag, B.; Cools, J.; Sciot, R.; Prenen, H.; Vandenberghe, P.; Wozniak, A.; Schöffski, P.; Marynen, P.; Debiec-Rychter, M. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin. Cancer Res., 2008, 14, 5749-5758.
143. Demetri, G. D.; Lo Russo, P.; MacPherson, I. R. J.; Wang, D.; Morgan, J. A.; Brunton, V. G.; Paliwal, P.; Agrawal, S.; Voi, M.; Evans, T. R. J. Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors. Clin. Cancer Res., 2009, 15, 6232-6240.
144. Braconi, C.; Bracci, R.; Cellerino, R. Molecular targets in gastrointestinal stromal tumors (GIST) therapy. Curr. Cancer Drug Targets, 2008, 8, 359-366.
145. Reichardt, P.; Montemurro, M.; Gelderblom, H.; Blay, H.; Rutkowski, P.; Bui, B.; Hartmann, J. T.; Pink, D.; Leyvraz, S.; Schütte, J. Sorafenib fourthline treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: a retrospective analysis. J. Clin. Oncol., 2009, 27, 15s, Abstract 10564.
146. Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rösel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K.-H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F.; Marmé, D. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res., 2000, 60, 2178-2189. (Pubitemid 30225181)
147. Joensuu, H.; De Braud, F.; Coco, P.; De Pas, T.; Putzu, C.; Spreafico, C.; Bono, P.; Bosselli, S.; Jalava, T.; Laurent, D.; Casali, P. G. Phase II, openlabel study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann. Oncol., 2008, 19, 173-177.
148. Soria, J. C.; Massard, C.; Magné, N.; Bader, T.; Mansfield, C. D.; Blay, J. Y.; Bui, B. N.; Moussy, A.; Hermine, O.; Armand, J. P. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur. J. Cancer, 2009, 2333-2341.
149. Le Cesne, A.; Blay, J. Y.; Bui, B. N.; Bouché, O.; Adenis, A.; Domont, J.; Cioffi, A.; Ray-Coquard, I.; Lassau, N.; Bonvalot, S.; Moussy, A.; Kinet, J. P.; Hermine, O. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur. J. Cancer, 2010, 46, 1344-1351.
150. von Bubnoff, N.; Gorantla, S. H.; Kancha, R. K.; Lordick, F.; Peschel, C.; Duyster J. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia, 2005, 19, 1670-1671. (Pubitemid 43090414)
151. Kim, K. P.; Ryu, M. H.; Yoo, C.; Ryoo, B. Y.; Choi, D. R.; Chang, H. M.; Lee, J. L.; Beck, M. Y.; Kim, T. W.; Kang, Y. K. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. Cancer Chemother. Pharmacol., 2010, doi: 10.1007/s00280-010- 1479-6.
152. Schlemmer, M.; Schinwald, N.; Bruns, C.; Berger, F.; Reichardt, P. Response to Nilotinib as a First-Line Treatment for Metastatic Gastrointestinal Stromal Tumors. J. Gastrointest. Cancer, 2010, doi 10.1007/s12029-010-9208-2.
153. Cassier, P.; Pissaloux, D.; Alberti, L.; Ray-Coquard, I.; Blay, J. Y. Targeted treatment of rare connective tissue tumors and sarcomas. Bull. Cancer, 2010, 97, 693-700.
154. Piao, W.; Wang, Y.; Adachi, Y.; Yamamoto, H.; Li, R.; Imsumran, A.; Li, H.; Maehata, T.; Ii, M.; Arimura, Y.; Lee, C. T.; Shinomura, Y.; Carbone, D. P.; Imai, K. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol. Cancer Ther., 2008, 7, 1483-1493.
155. Le Cesne, A.; Ray-Coquard, I.; Bui, B. N.; Adenis, A.; Rios, M.; Bertucci, F.; Duffaud, F.; Chevreau, C.; Cupissol, D.; Cioffi, A.; Emile, J. F.; Chabaud, S.; Pérol, D.; Blay, J. Y.; French Sarcoma Group. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol., 2010, 11, 942-949.
156. Fumo, G.; Akin, C.; Metcalfe, D. D.; Neckers, L. 17-Allylamino-17- demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood, 2004, 103, 1078-1084. (Pubitemid 38129574)
157. Bauer, S.; Yu, L. K.; Demetri, G. D.; Fletcher, J. A. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res., 2006, 66, 9153-9161. (Pubitemid 44521135)
158. Sambol, E. B.; Ambrosini, G.; Geha, R. C.; Kennealey, P. T.; Decarolis, P.; O'Connor, R.; Wu, Y. V.; Motwani, M.; Chen, J. H.; Schwartz, G. K.; Singer, S. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res., 2006, 66, 5858-5866. (Pubitemid 43927140)
159. van der Bruggen, P.; Traversari, C.; Chomez, P.; Lurquin, C.; De Plaen, E.; Van den Eynde, B.; Knuth, A.; Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 1991, 254, 1643-1647. (Pubitemid 21917508)
160. Caballero, O. L.; Chen, Y. T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci., 2009, 100, 2014-2021.
161. Simpson, A. J. G.; Caballero, O. L.; Jungbluth, A.; Chen, Y.-T.; Old, L. J. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer, 2005, 5, 615-625. (Pubitemid 41081387)
162. Perez, D.; Hauswirth, F.; Jäger, D.; Metzger, U.; Samartzis, E. P.; Went, P.; Jungbluth, A. Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors. Int. J. Cancer, 2011, 128, 2947-2952.
163. Chi, P.; Chen, Y.; Zhang, L.; Guo, X.; Wongvipat, J.; Shamu, T.; Fletcher, J. A.; Dewell, S.; Maki, R. G.; Zheng, D.; Antonescu, C. R.; Allis, C. D.; Sawyers, C. L. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature, 2010, 467, 849-853.
164. Heinrich, M. C.; Corless, C. L. Cancer: Oncogenes in context. Nature, 2010, 467, 796-797.